Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Regulatory

Pharmacovigilance

The collection and analysis of reports of suspected adverse reactions after authorisation. Establishes that an event has been reported and, for an event named in a warning, is confounded by reporting…

Document identifier
CEI-GT-179
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Pharmacovigilance

§1.2Category

Regulatory — Terms describing the status of a compound before a competent authority.

§1.3Related terms

  • Boxed warning — The most prominent warning a competent authority can require in product information. Signals regulatory concern; does not itself establish that the risk is realised in…
  • Notoriety bias — Increased reporting of an adverse event following publicity about it, which inflates a pharmacovigilance signal without any change in incidence.
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.